Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)

CompletedOBSERVATIONAL
Enrollment

135

Participants

Timeline

Start Date

August 16, 2016

Primary Completion Date

April 29, 2018

Study Completion Date

April 29, 2018

Conditions
Breast Cancer
Interventions
DRUG

Definity

The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.

Trial Locations (1)

90033

USC Department of Radiology, Los Angeles

All Listed Sponsors
collaborator

Wright Foundation

UNKNOWN

lead

University of Southern California

OTHER

NCT02887937 - Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS) | Biotech Hunter | Biotech Hunter